Assistant Professor, Medicine, Baylor College of Medicine
Oncology
Dr. Nicholas Mitsiades, MD
|
|
Give Review
Nicholas Mitsiades practices Oncology. Nicholas Mitsiades, MD has written publications. He has 101 publications published with PubMed. The lastest paper is: 'The mercy of adrenocortical tumor cells on lymphocytes.' He accepts Medicare.
Publications
- Androgen Receptor Is the Key Transcriptional Mediator of the Tumor Suppressor SPOP in Prostate Cancer.
- An epigenomic approach to therapy for tamoxifen-resistant breast Cancer.
- PROTEIN KINASE C INHIBITORS SENSITIZE GNAQ MUTANT UVEAL MELANOMA CELLS TO IONIZING RADIATION.
- Metabolomic Profiling Identifies Biochemical Pathways Associated with Castration-Resistant Prostate Cancer.
- A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate Cancer.
- Prostate Cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover.
- The role of Fas and FasL as mediators of antiCancer chemotherapy.
- 2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27.
- The role of apoptosis-inducing receptors of the tumor necrosis factor family in thyroid Cancer.
- Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias.
- Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug.
- Apoptosis induced by FasL and TRAIL/Apo2L in the pathogenesis of thyroid diseases.
- TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.
- The Gem GTP-binding protein promotes morphological differentiation in neuroblastoma.
- Fas-mediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor protein and Bcl-2.
- Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell Malignancies.
- Fas/Fas ligand-associated apoptosis in experimental autoimmune uveoretinitis in rodents: role of proinflammatory corticotropin-releasing hormone.
- Ewing's Sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
- Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity.
- Circulating thyroglobulin transcytosed by thyroid cells in complexed with secretory components of its endocytic receptor megalin.
- Fas ligand expression in thyroid follicular cells from patients with thionamide-treated Graves' disease.
- Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
- Caffeic acid phenethyl ester induces leukocyte apoptosis, modulates nuclear factor-kappa B and suppresses acute inflammation.
- Fas-mediated apoptosis in Ewing's Sarcoma cell lines by metalloproteinase inhibitors.
- Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion.
- The mercy of adrenocortical tumor cells on lymphocytes.
- Fas ligand is present in tumors of the Ewing's Sarcoma family and is cleaved into a soluble form by a metalloproteinase.
- Fas/Fas ligand up-regulation and Bcl-2 down-regulation may be significant in the pathogenesis of Hashimoto's thyroiditis.
- Chronic effects of a nonpeptide corticotropin-releasing hormone Type I receptor antagonist on pituitary-adrenal function, body weight, and metabolic regulation.
- Hyperthyroidism in McCune-Albright syndrome with a review of thyroid abnormalities sixty years after the first report.
- Dopamine affects the in vitro basal secretion of rat placenta opioids in an opioid and dopamine receptor Type-specific manner.
- Recurring oral giant cell lesion in a child with X-linked hypophosphatemic rickets: clinical manifestation of occult parathyroidism?
- Skin manifestations of Cushing disease in children and adolescents before and after the resolution of hypercortisolemia.
- Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance.
- NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.
- P2X7 polymorphism and chronic lymphocytic leukaemia.
- Novel biologically based therapies for Waldenstrom's macroglobulinemia.
- Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations.
- Proteomic Analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasias.
- JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells.
- Molecular sequelae of histone deacetylase inhibition in human malignant B cells.
- Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein.
- VEGF-dependent conjunctivalization of the corneal surface.
- Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells.
- Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays.
- Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced Diabetes.
- Constitutive nuclear factor-kappaB activity is crucial for human retinoblastoma cell viability.
- CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling.
- The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.
- Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.
- Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
- Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.
- Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
- Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells.
- beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells.
- Cytokines modulate telomerase activity in a human multiple myeloma cell line.
- Apoptotic signaling induced by immunomodulatory thalidomide Analogs in human multiple myeloma cells: therapeutic implications.
- Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications.
- Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells.
- NF-kappa B as a therapeutic target in multiple myeloma.
- Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic reti...
- Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression.
- Effect of imatinib mesylate (Gleevec) on anaplastic thyroid carcinoma cell lines.
- Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT sig...
- Immunomodulatory drug costimulates T cells via the B7-CD28 pathway.
- Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells.
- Identification of genes modulated in multiple myeloma using genetically identical twin samples.
- Insights into the multistep transformation of MGUS to myeloma using microarray expression Analysis.
- Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.
- Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma.
- Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas.
- A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
- Treatment of hematologic Malignancies and solid tumors by inhibiting IGF receptor signaling.
- Proteasome inhibition as a therapeutic strategy for hematologic Malignancies.
- Novel histone deacetylase inhibitors in the treatment of thyroid Cancer.
- Thyroid carcinoma cells and Fas-mediated apoptosis.
- Human retinoblastoma cells are resistant to apoptosis induced by death receptors: role of caspase-8 gene silencing.
- Focus on multiple myeloma.
- Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy.
- CC-5013 (Celgene).
- The Akt pathway: molecular targets for anti-Cancer drug development.
- Thymoma-associated multiorgan autoimmunity: a graft-versus-host-like disease.
- Inhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis.
- Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.
- Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate Cancer: a case control study.
- Total and high-molecular-weight adiponectin in breast Cancer: in vitro and in vivo studies.
- Proteasome inhibition as a new therapeutic principle in hematological Malignancies.
- Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM).
- Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
- Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional Analysis.
- Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation.
- Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate Cancer.
- Circulating Adiponectin Is Inversely Associated with Risk of Thyroid Cancer: In Vivo and in Vitro Studies.
- GenoType-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy.
- Integrative genomic profiling of human prostate Cancer.
- Tumor cell-specific bioluminescence platform to identify stroma-induced changes to antiCancer drug activity.
- A T cell-binding fragment of fibrinogen can prevent autoimmunity.
- Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.
- In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465.
- Role of alpha 4 integrin (CD49d) in the pathogenesis of diabetic retinopathy.
Conditions Treated
- Anal and Rectal Cancer
- Anemia
- Bladder Cancer
- Colorectal Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Memorial Sloan-Kettering Cancer Center -
Beth Israel Deaconess Medical Center -
University of Athens
Drug Facts
| NPI NUMBER | 1508090754 | |
| NPPES Provider LastName | MITSIADES | |
| NPPES Provider FirstName | NICHOLAS | |
| NPPES Provider ZIPCode | 770303411 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 21.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1508090754 |
| Last Name Of The Provider | MITSIADES |
| First Name Of The Provider | NICHOLAS |
| View All |
Similar Doctors
|
|
Dr. Daniel Lehane, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jianjun Gao, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rajul Jain, MD |
|
|
Dr. Wadih Arap, MD
This Doctor is OpenDoctor Recommended.
|